Kornimate/medical-research-clean huggingface dataset:
next generation sequencing screening for embryonic ploidy status

Conditions: Infertility

Summary: to evaluate the benefits of using next generation sequencing to assess embryonic aneuploidy. all viable blastocysts will be biopsied and cryopreserved for future transfer. after the final embryo is cryopreserved, patients will be randomized to either the intervention group or the control group. patients and doctors are blinded to the randomization until study completion. a double embryo transfer (det) will be performed with either screened or unscreened embryos depending on randomization. a single embryo transfer (set) may occur in cases where only one embryo is available for transfer.


Eligibility criteria:
inclusion criteria: * patient undergoing ivf/ccs (no pgd banking) * patient meets asrm guidelines for double embryo transfer (det) * donor sperm ok * amh ≥ 1.2 * fsh ≤ 12 * bafc ≥12 * max 1 prior failed ivf cycle for patients 35-45 years old * patient \<35 years old must have 1 prior failed ivf cycle exclusion criteria: * chronic endometrial insufficiency * use of oocyte donor or gestational carriers * medical contraindications to double embryo transfer (det) * male factor (\<100,000 sperm or surgical sperm) * communicating hydrosalpinx (on hsg) * single gene disorders or sex selection

Keywords: next generation sequencing embryonic aneuploidy
comparison of the use of energy substrates and hormonal regulation of blood sugar during exercise of increasing intensity between children with type 1 diabetes and non-diabetic control children.

Conditions: Type 1 Diabetes

Summary: the type 1 diabetes is a common chronic disease characterised by the stop of production of insulin by the pancreas. a lot of factors modify blood glucose. the objective is to study the effect of type 1 diabetes on the use of energy substrates (fats and carbohydrates) during exercise of increasing intensity by a comparison with non-diabetic controls children.

the type 1 diabetes is a common chronic disease characterised by the stop of production of insulin by the pancreas. a lot of factors modify blood glucose. the objective is to study the effect of type 1 diabetes on the use of energy substrates (fats and carbohydrates) during exercise of increasing intensity by a comparison with non-diabetic controls children.

Eligibility criteria:
inclusion criteria: * children between 6 and 12 years * tanner stage \<t2 * type 1 diabetes for more than 1 year for infants with type 1 diabetes exclusion criteria: * tanner stage \> ou = t2 * obesity * hormonal disease * disease who prevent doing exercise

Keywords: type 1 diabetes control physical activity substrate utilization hormonal regulation
effects of laser therapy on muscle function in copd patients

Conditions: Chronic Obstructive Pulmonary Disease; Fatigue

Summary: light-emitting diodes (leds) have been used to minimize muscle fatigue in athletes and healthy subjects. patients with chronic obstructive pulmonary disease (copd) are susceptible to early muscle fatigue. the objective of this study is to assess the acute effects of leds on muscle function, exercise capacity, and cardiorespiratory responses during isometric and dynamic exercise in patients with copd. this study will assess 30 patients with moderate to severe obstruction (fev1 ≤ 70% predicted). isometric and dynamic protocols will be conducted in two visits each, for a total of four visits a week a part. first, a venous blood sample will be taken from the patients. the isometric protocol will start with the determination of the maximum voluntary isometric contraction (mivc) to determine the workload (60% of mivc) for the isometric endurance test (iet). patients will be randomized to receive either the placebo or led application. immediately after finishing this procedure, the patients will carry out the iet until the limit of tolerance or until a 20% fall of strength is observed. after the test, another blood sample will be taken. in the other visit (one week later), the same order of procedures will be performed, except with the opposite (led or placebo). for the dynamic protocol, the same procedures described above will be followed except with the maximal incremental cycle ergometer test used instead of the iet. the electromyography will be recorded during the isometric and dynamic protocols. differences in muscle function, exercise capacity, and cardiorespiratory responses between the led and placebo applications will be analyzed. the therapeutic effects of led could minimize muscle fatigue in patients with copd by increasing exercise tolerance.


Eligibility criteria:
inclusion criteria: * 35 patients will be selected (see sample calculation in section 6) who have moderate to severe obstruction (fev1 ≤ 70% predicted) and stable disease, as suggested by the absence of changes in medication in the last 4 weeks. exclusion criteria: * ischemic heart disease, recent surgery, neuro-muscular or orthopedic that limit the performance of the protocol. * patients will only be included in the study after signing the consent form.

Keywords: chronic obstructive pulmonary disease fatigue laser therapy
comparison of robot-assisted gait training according to gait speed in participants with stroke

Conditions: Stroke

Summary: comparison of the experimental group that applied the speed of the robot-assisted gait training constantly and the control group that applied the gradual increase of the speed of the robot-assisted gait training.


Eligibility criteria:
inclusion criteria: * hemiplegic patients secondary to first cerebrovascular accidents * functional ambulation category score ≥ 3 exclusion criteria: * history of surgery of affected lower limb * fracture of affected lower limb

Keywords: robot-assisted gait training stroke gait speed
the effects of carperitide on short and long-term prognosis in patients with both cardiac and renal failure

Conditions: Heart Failure; Renal Failure

Summary: carperitide (alpha-human atrial natriuretic peptide) improves systemic hemodynamics in patients with heart failure through a vasodilatory action, a natriuretic action, and inhibition of the renin-angiotensin-aldosterone system and has been widely-used in japan. however, a paucity of report is available on the effects of carperitide on short and long-term prognosis in patients with both cardiac and renal failure. the purpose of this study is to evaluate the effects of carperitide therapy on short and long-term prognosis in patients with both cardiac and renal failure, in comparison with standard therapy.


Eligibility criteria:
inclusion criteria: * heart failure of any etiology, diagnosed according to framingham criteria * estimated gfr \</= 60 ml/min/1.73 m2) exclusion criteria: * severe heart failure required percutaneous cardiopulmonary bypass support (pcps) * end-stage renal failure on maintenance dialysis * severe hepatic dysfunction * severe anemia * allergic history of carperitide * pregnant women

Keywords: natriuretic peptides heart failure renal failure
evaluation of quality of life and period of hospitalization by education

Conditions: Colorectal Cancer

Summary: patients with colorectal cancer prior to stoma surgery are randomized to different preoperative education programs: (a) specific preoperative education, (b) standard preoperative education. outcome measures are quality of life, period of hospitalization and complication rates.

the present study is initiated to evaluate quality of life, period of hospitalization and complication rates in patients with colorectal cancer receiving treatment with stoma surgery. prior to surgery patients are randomized to different preoperative education programs. in arm a patients receive a new specific education program (krankenhaus nordwest concept) conducted by a specialized therapist (stoma-therapist). in arm b patients receive the standard preoperative education program. standardized questionnaires are used to evaluate quality of life and period of hospitalization at baseline and four weeks after surgery in arm a vs. arm b

Eligibility criteria:
inclusion criteria: * planned stoma * colorectal cancer, from resection of left hemi-colon aboral a. colica media * patients speaking german and living in germany * ecog ≤ 3 * informed consent * standard education program exclusion criteria: * patients treated with stoma by emergency * patients with dementia * status post stoma * patients in contact with a stoma-therapist * recurrence of colorectal cancer

Keywords: stoma quality of life
the role of consolidative autologous stem cell transplantation after first-line therapy in peripheral t cell lymphoma

Conditions: Peripheral T Cell Lymphoma

Summary: the role of autologous stem cell transplantation (asct) in the first remission (cr1 \& pr1) of peripheral t-cell lymphomas (ptcls) is not well defined. this study analyzed the impact of asct on the clinical outcomes of patients with newly diagnosed ptcl in cr1 and pr1.


Eligibility criteria:
inclusion criteria: * patients with confirmed pathological diagnosis of aggressive ptcl * age 18-65 years old * achieving cr or pr after first-line therapy exclusion criteria: * subtypes with a more indolent course, including precursor t/natural killer neoplasms, t-cell large granular lymphocytic leukemia, mycosis fungoides other than transformed mycosis fungoides, sézary syndrome, and primary cutaneous cd30-positive disorders.

Keywords: autologous stem cell transplantation
a study of ixazomib in adult patients with lymphoma

Conditions: Lymphoma

Summary: this study is an open-label, multicenter, phase 1, dose-escalation study of ixazomib in adult patients with lymphoma. this study will be the first to administer ixazomib to patients with lymphoma.


Eligibility criteria:
inclusion criteria: 1. male or female patients 18 years or older. 2. eastern cooperative oncology group performance status 0-2. 3. patients must have a confirmed diagnosis of lymphoma that is relapsed and/or refractory after at least 2 prior chemotherapeutic regimens and for which no curative option exists. patients with waldenstrom's macroglobulinemia are not eligible for enrollment in this study. patients with hodgkin lymphoma are considered eligible for this study. 4. suitable venous access for pk and pharmacodynamic evaluations. 5. female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse. male patients who agree to to practice 2 effective methods of contraception or abstain from heterosexual intercourse. 6. voluntary written consent must be obtained. 7. adequate blood and chemistry values during the screening period: * absolute neutrophil count (anc) ≥ 1,500/mm3; platelet count ≥ 100,000/mm3. * total bilirubin must be ≤ 1.5 × the upper limit of the normal range upper limit of normal (uln). * alanine aminotransferase (alt) or aspartate aminotransferase (ast) must be ≤ 2.5 × the upper limit of normal (uln). ast and alt may be elevated up to 5 times the upper limit of normal if their elevation can be reasonably ascribed to the presence of metastatic disease. * calculated creatinine clearance ≥ 30 ml/minute. exclusion criteria: 1. peripheral neuropathy ≥ grade 2. 2. female patients who are lactating or have a positive serum pregnancy test during the screening period . 3. major surgery within 14 days before the first dose of treatment. 4. infection requiring systemic antibiotic therapy or other serious infection within 14 days before the first dose of study treatment. 5. life-threatening illness unrelated to cancer. 6. diarrhea \> grade 1 based on the nci ctcae categorization. 7. systemic antineoplastic therapy/or radiotherapy within 21 days before the first dose of study treatment. 8. systemic treatment with prohibited medications. 9. patient has symptomatic brain metastases. 10. evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (chf), angina, or myocardial infarction within the past 6 months. 11. qtc \> 470 milliseconds (msec) on a 12-lead electrocardiogram (ecg) obtained during the screening period. 12. known human immunodeficiency virus (hiv), hepatitis b or hepatitis c positive. 13. any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol. 14. treatment with any investigational products within 28 days before the first dose of study treatment.
study to evaluate percussive ventilation breathhold to improve lung stereotactic ablative radiotherapy

Conditions: Lung Cancer

Summary: the purpose of this research is to evaluate and determine the rate of successful administration of percussive ventilation breathhold (pvb) to allow for more accurate radiotherapy for lung tumors.

primary objective(s) * to determine the rate of successful administration of the pvb-sabr in lung cancer patients. * to determine the rate of successful administration of pvb in healthy volunteers for 5 minutes secondary objective(s) * to determine the rate of successful administration of pvb in healthy volunteers for 10 minutes as well as for patients' successfully completing the technique for 5 and 10 minutes. * to collect exploratory clinical (both arms) and dosimetric data from lung cancer patients using pvb-sabr.

Eligibility criteria:
inclusion criteria: arm 1: healthy volunteers age 18 or older arm 1: ability to understand and the willingness to sign (personally or by a legal authorized representative) the written irb approved informed consent document. arm 2: patients with a diagnosis of primary lung cancer or lung metastases of any primary tumor origin arm 2: patients deemed clinically eligible to be treated with standard of care lung sabr for patient arm arm 2: patients of any gender age 18 or older arm 2: patients with ecog performance status 0-2 and select patients with performance status 3 deemed to be suitable candidates based on common sense clinical judgment on the risks versus benefits of sabr arm 2: ability to understand and the willingness to sign (personally or by a legal authorized representative) the written irb approved informed consent document. exclusion criteria: arm 1: no pregnant individuals. all individuals of child bearing potential (last menstrual period within the previous 12 months and not surgically sterile) will be tested for pregnancy and documented by study team. arm 2: patients clinically deemed ineligible for standard of care lung sabr treatment for the patient arm (for example, excessive tumor size, individuals who are pregnant or breast feeding, severe pulmonary fibrosis are relative contraindications for lung sabr and are part of standard of care clinical decision making). arm 2: patients with newly-developed pneumothorax arm 2: patients with critical acute illness precluding sabr in the judgment of the treating physician (examples could include active pulmonary embolism and infection requiring inpatient care) arm 2: patients with ecog performance status 4
project voice: vascular outcomes improvement through collection of patient reported data

Conditions: Peripheral Artery Disease

Summary: the purpose of this study is to evaluate the feasibility of a digital health platform coupled with walking activity tracking for patients with peripheral artery disease (pad) and symptoms limited to claudication.

this is a two center, non-blinded, 2 period randomized crossover trial. 50 patient subjects are planned. patient participants will be identified and recruited from clinical environments (including clinics and diagnostic testing departments) at participating sites. diagnosis and testing will occur through usual clinical care, and participants will not incur financial costs related to participation. a crossover design will be utilized, where all participants will use the voice platform with activity tracking for 35 days and usual care for 30 days. randomization will determine the order in which participation in the voice phase versus the usual care phase occur. randomization will occur using a closed envelope system. for patients in the voice platform group, data collection will occur over a total of 35 days, including an initial 5-day "run in" period during which participants will orient themselves to the system. each provider participant will receive a single end-user survey evaluating voice from their perspective. screening of patients electronic medical records will be done to determine subject eligibility. subjects who meet all inclusion criteria will be approached to participate. total duration of subject participation will be 9 weeks during the control and intervention phases, with a final follow-up survey at 6 months post-enrollment.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of symptomatic pad with claudication * ankle- brachial index (abi) ≤ 0.9 or non-compressible leg arteries * walking exercise therapy recommended as treatment for pad by the healthcare provider * willingness to be randomized to voice platform or control group * ability to access the internet * willing to sign an informed consent exclusion criteria: * walking exercise therapy not recommended due to contraindication or any other reason * wheelchair dependence or inability to walk unassisted * presence of foot ulcers, wounds, or gangrene * history of major extremity amputation * lack of objective physiologic data validating pad diagnosis * claudication symptoms due to diagnoses other than pad (i.e., popliteal entrapment syndrome) * inability to speak or read english * severe mental illness * inability to give informed consent

Keywords: peripheral artery disease claudication supervised exercise therapy walking quality of life
risk factors for ards in patients with acute necrotizing pancreatitis

Conditions: Acute Necrotizing Pancreatitis; Acute Respiratory Distress Syndrome

Summary: try to collect about 350 cases of acute necrotizing pancreatitis at the first affiliated hospital with nanjing medical university and nanjing general hospital of nanjing military command. then the investigators studied the incidence and the risk factors of ards in patients with acute necrotizing pancreatitis.

using electronic patient data monitoring systems, the investigators reviewed all patients with a diagnosis of pancreatitis admitted to surgical wards or icus at the first affiliated hospital with nanjing medical university and nanjing general hospital of nanjing military command from january 1, 2009, to october 31, 2015. inclusion criteria were adult patients (age \>18 years) with acute necrotizing pancreatitis. exclusion criteria were as follows : 1) lack of radiologic evidence to diagnose acute necrotizing pancreatitis, 2) presence of ards before admission to hospitals, 3) unable to partner treatment and leaving hospitals, 4) transferring to the investigators' hospitals after treatment, 5) missing other necessary data, and 6) pregnancy. for enrolled patients, general clinical characteristics were collected. patients were categorized into two groups according to ards or non-ards, and the differences of these characteristics between two groups were evaluated. potential risk factors were collected and studied by using multiple logistic regression analysis.

Eligibility criteria:
inclusion criteria: * adult patients (age \>18 years) with acute necrotizing pancreatitis exclusion criteria: * lack of radiologic evidence to diagnose acute necrotizing pancreatitis, * presence of ards before admission to hospitals, * unable to partner treatment and leaving hospitals, * transferring to the investigators' hospitals after treatment, * missing other necessary data, * pregnancy.
c-beyond: efficacy and safety of bem/rzr vs. sof/vel in subjects with chronic hcv

Conditions: HEPATITIS C VIRUS CHRONIC INFECTION

Summary: the purpose of this study is to compare the efficacy and safety of bem/rzr to sof/vel in adults with chronic hcv.


Eligibility criteria:
key inclusion criteria: * use of adequate contraception for females of childbearing potential * must be direct-acting antiviral (daa)-treatment-naïve (never exposed to an approved or experimental daa for hcv) * documented medical history compatible with chronic hcv * either no liver cirrhosis or with compensated liver cirrhosis * if hiv-1-positive, must meet the following 2 criteria: 1. antiretroviral (arv) regimen for \>8 weeks prior to screening visit, with cd4 t-cell count \>200 cells/mm3 and plasma hiv-1 rna \<lloq 2. suitable arv treatment and not taking any contraindicated medications key exclusion criteria: * pregnant or breastfeeding * co-infected with hepatitis b virus * abuse of alcohol and/or illicit drug use that could interfere with adherence to study requirements as judged by the investigator * requirement of any prohibited medications * use of other investigational drugs within 30 days of dosing * history or signs of decompensated liver disease (decompensated cirrhosis) * history of hepatocellular carcinoma (hcc) * any other clinically significant medical condition that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results
remote monitoring of cardiac mechanics in heart failure patients

Conditions: Heart Failure; Heart Failure - NYHA II - IV

Summary: heart failure is a severe heart disease, where the heart's ability to pump blood is unsatisfactory. the consequence is a high risk of hospitalization and death. heart failure is treated with medicine which relieves symptoms and slows down the disease progression. this medical treatment needs routine adjustment, but in many cases, this adjustment is not done timely, which results in life treating conditions where the patients need acute hospitalization. remote health monitoring of hf patients has the potential to ensure timely adjustment. however, only sensors placed inside the blood vessels of the lung, have been shown effective. the disadvantage is that the placement of the sensor requires surgery. this makes the method costly and poses a risk for the patient. the aim of the current project is to develop a small intelligent patch, which can measure the heart's function from the outside of the body. the method will be low-cost, simple to use and will not pose a risk to the patient.

the goal of this observational study is to gather data from heart failure participants, and to investigate whether it is possible to detect early alterations in heart failure based on this data. the main goals are * investigate whether parameters extracted from the measured data provide information regarding heart failure alterations * investigate if it is possible to detect alterations at early stages the gathered data will be measured from a little sensor placed on sternum measuring acceleration (seismocardiography (scg)) and electrocardiography (ecg) to provide an impression of the heart\&amp;#39;s mechanical function and electrical function, respectively. this data from the sensor will be analyzed with respect to other parameters obtained from, among others, echocardiography, total blood volume, changes in medical therapy, and hospitalization. the included heart failure participants should be in the age group 18-90 years and in new york heart association functional classification (nyha) class ii or higher. participants will wear the sensor to measure the participant\&amp;#39;s cardiac mechanics and electronics simultaneously. the participants will: * wear the sensor for a period of 30 days from discharge or visit to heart failure clinic. the sensor will measure scg and ecg for a short period (less than 30 seconds) once every hour, * fill out questionnaires at first and last day of the study * undergo echocardiography at first day and last day of the study * not change everyday life because of the sensor

Eligibility criteria:
inclusion criteria: * nyha class ii or higher * 18-90 years old exclusion criteria: * pregnancy * drug addiction defined as the use of cannabis, opioids, or other drugs * mechanical heart valves * in dialysis * not possible to obtain clinical echocardiography of sufficient quality * lack of ability to coorperate

Keywords: heart failure remote monitoring cardiac mechanics